While Jazz Pharmaceuticals plc has underperformed by -0.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, JAZZ rose by 33.89%, with highs and lows ranging from $182.99 to $95.49, whereas the simple moving average jumped by 31.00% in the last 200 days.
On November 24, 2025, UBS Downgraded Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to Neutral. A report published by Deutsche Bank on July 15, 2025, Initiated its previous ‘Buy’ rating for JAZZ. UBS also Upgraded JAZZ shares as ‘Buy’, setting a target price of $179 on the company’s shares in a report dated March 07, 2025. Wells Fargo February 13, 2025d its ‘Equal Weight’ rating to ‘Overweight’ for JAZZ, as published in its report on February 13, 2025. Morgan Stanley’s report from December 12, 2024 suggests a price prediction of $175 for JAZZ shares, giving the stock a ‘Overweight’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Jazz Pharmaceuticals plc (JAZZ)
Further, the quarter-over-quarter increase in sales is 6.74%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Jazz Pharmaceuticals plc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -9.06% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.44, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and JAZZ is recording an average volume of 1.00M. On a monthly basis, the volatility of the stock is set at 3.35%, whereas on a weekly basis, it is put at 2.98%, with a loss of -1.21% over the past seven days. Furthermore, long-term investors anticipate a median target price of $214.13, showing growth from the present price of $164.89, which can serve as yet another indication of whether JAZZ is worth investing in or should be passed over.
How Do You Analyze Jazz Pharmaceuticals plc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.56%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 100.49% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
JAZZ shares are owned by institutional investors to the tune of 100.49% at present.
